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Abstract Multiple sclerosis (MS) has a profound impact
on health-related quality of life (HRQoL), a comprehensive
subjective measure of the patient’s health status. Assess-
ment of HRQoL informs on the potential advantages and
disadvantages of disease-modifying drugs (DMDs) beyond
their effects on observer-based disability and magnetic
resonance imaging abnormalities. This article reviews
published data from randomized controlled trials and
observational studies regarding the effects of currently
available DMDs on HRQoL. Data indicate that DMD
treatment is associated with prevention of worsening or
with improvement of HRQoL, and that, in general, second-
line DMDs may have a greater impact on HRQoL than
first-line DMDs. In clinical practice, monitoring of HRQoL
provides clinicians with unique information regarding
disease impact and potential benefits and adverse effects of
DMD treatment that may not be obtained otherwise; it
might also permit early detection of an unfavorable disease
course. It is suggested to assess HRQoL at the time of
diagnosis and before starting or switching DMD treatment.
Regular HRQoL measurements contribute to a compre-
hensive clinical evaluation, and may help to elucidate and
quantify the patient’s contribution to shared decision
making regarding DMD treatment. Further studies are
needed to better determine the role of HRQoL assessments
in daily MS care.
Key Points
Health-related quality of life (HRQoL) is a patient-
reported outcome that comprises a comprehensive
subjective measure of the patient’s health status.
HRQoL provides information on beneficial and
adverse treatment effects from the patient’s
perspective, complementing observer-based outcome
measures.
Assessment of HRQoL contributes to an integrated
evaluation of the effects of treatment with disease-
modifying drugs (DMDs), predicts disability
progression, and helps to formalize patients’ input in
shared decision making.
Data from randomized controlled trials and
observational studies indicate that in relapsing-
remitting MS, second-line DMDs are generally more
strongly associated with prevention of worsening or
with improvement of HRQoL than first-line DMDs.
1 Introduction
Multiple sclerosis (MS) is a chronic, inflammatory,
demyelinating and degenerative disorder of the central
nervous system [1]. Although its natural history is highly
variable, in the majority of patients MS leads to sub-
stantial disability. Approximately 85–90% of patients
present with relapsing-remitting MS (RRMS), which is
characterized by recurrent episodes of new or worsening
symptoms, followed by at least partial recovery;
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conversion to secondary progressive MS (SPMS) even-
tually occurs in approximately 75% of these patients [1].
The remaining 10–15% present with primary progressive
MS (PPMS), which is characterized by progressive dis-
ability from disease onset [1]. The number of disease-
modifying drugs (DMDs) available for the treatment of
MS has increased considerably in recent years. Interferon
(IFN) b-1a, INFb-1b, pegylated INFb-1a, glatiramer
acetate (GA), natalizumab, fingolimod, dimethyl fumarate
(DMF), teriflunomide, alemtuzumab, daclizumab and
ocrelizumab are now approved for the treatment of RRMS
in many countries [2, 3]. Ocrelizumab is the only drug
approved for PPMS. Mitoxantrone is a general immuno-
suppressive drug used for the treatment of rapidly wors-
ening RRMS and is currently the only agent approved for
the treatment of SPMS [2], although IFNb-1b and sub-
cutaneous IFNb-1a are approved for the treatment of
SPMS with relapses.
Annualized relapse rate (ARR), time to sustained dis-
ability progression, and magnetic resonance imaging
(MRI) abnormalities are widely used to describe disease
activity in MS, and to assess the efficacy of DMDs in
clinical trials and the effectiveness of their use in daily
practice. A widely applied measure of MS-related dis-
ability is the Expanded Disability Status Scale (EDSS) [4].
EDSS scoring is based on neurological examination and
ambulation/mobility status [4]; the total score ranges from
0 (normal) to 10 (death from MS) in 0.5-unit increments.
This ordinal scale is often criticized for its reliance on
walking as the main measure of disability, and its under-
estimation of fatigue, depression and cognitive symptoms;
EDSS scores of 0.0–3.5 are based on neurological
impairments, 4.0–5.5 on walking distances, 6.0–7.0 on
walking aids, and 7.5 upwards on upper limb function.
However, observer-reported outcomes, such as ARR and
time to sustained disability progression, do not fully reflect
the overall impact of MS on patients [5]. Accordingly,
patient-reported outcomes (PROs) are increasingly being
used in clinical trials and clinical practice [5]. A PRO is
any report of the status of a patient’s health condition that
comes directly from the patient, without interpretation of
the patient’s response by a clinician or anyone else [5]. A
frequently used PRO is health-related quality of life
(HRQoL), which can be defined as the functional effect of
an illness and its consequent therapy upon a patient, as
perceived by the patient [6]. HRQoL is multidimensional,
encompassing physical and occupational function, psy-
chological state, social interaction and somatic sensation
[6]. Thus, HRQoL questionnaires aim to provide a broad,
comprehensive, subjective measure of disease impact (in-
cluding health dimensions that cannot be evaluated using
observer-based measures) as well as the impact of any
(side) effects of treatment [7–10].
Generic HRQoL instruments, such as the Sickness
Impact Profile (SIP) [11], the Medical Outcomes Study
Short-Form (36-item) Health Survey (SF-36) [12] and the
Medical Outcomes Study Short-Form (12-item) Health
Survey (SF-12) [13], have been used in MS studies. These
tools enable comparison of HRQoL with that in patients
with other conditions and the general population. However,
important domains unique to MS may be overlooked or
underestimated by these instruments. Furthermore, the SF-
36 has floor and ceiling effects that may limit its usefulness
in detecting treatment effects in patients with MS [14].
MS-specific instruments aim to provide a more com-
prehensive assessment and a greater sensitivity than gen-
eric measures (Table 1). The Multiple Sclerosis Quality of
Life-54 (MSQoL-54) questionnaire is a hybrid of the SF-36
and 18 additional MS-specific items, generating two sum-
mary scores: the physical composite score (PCS) and the
mental composite score (MCS) [15]. The Multiple
Sclerosis Quality of Life Inventory (MSQLI) is a 138-item
hybrid instrument comprising the SF-36 and nine symptom
subscales covering fatigue, pain, bowel function, bladder
function, emotional status, perceived cognitive function,
visual function, sexual satisfaction and social functioning
[16]. Both these instruments have been widely used in
patients with MS, and the SF-36 portion makes them useful
for comparative purposes. In addition to these hybrid
questionnaires, a large number of MS-specific HRQoL
instruments have been developed, including the Functional
Assessment of Multiple Sclerosis (FAMS) [17], the Ham-
burg Quality of Life Questionnaire in Multiple Sclerosis
(HAQUAMS) [18], the Leeds Multiple Sclerosis Quality of
Life (LMSQoL) questionnaire [19], the Multiple Sclerosis
Impact Scale-29 (MSIS-29) [20] and the Multiple Sclerosis
International Quality of Life (MusiQoL) questionnaire
[21]. These scales differ considerably in terms of domains
covered, complexity, recall period and the time needed to
complete them (Table 1). MS-specific instruments that
appear less commonly used include the ‘RAYS’ rating
scale [22], the Disability and Impact Profile (DIP) [23], and
the Patient-Reported Outcome Indices for Multiple
Sclerosis (PRIMUS) [24].
People with MS have a lower HRQoL than the general
population [25]. At low disability levels (EDSS B2.5),
differences are clear across all key domains, with an
average reduction of 30% compared with controls of a
similar age [25]. Patients with MS generally rate their
HRQoL as being lower than patients with other chronic
disorders, including epilepsy, diabetes and Parkinson’s
disease [26, 27]. This likely relates to the fact that in MS a
wide range of symptoms may have a negative impact on
HRQoL, including anxiety, bowel and/or bladder dys-
function, cognitive impairment, depression, disability,
fatigue, pain, sexual dysfunction, sleep quality and
586 P. J. Jongen
spasticity [28–44]. HRQoL correlates with EDSS score,
ARR and MRI abnormalities [45], and low HRQoL has
been shown to be an independent predictor of long-term
disability [46–48]. The clinical relevance of HRQoL in MS
is highlighted by the finding that the effect on quality of
life is rated by patients with MS as the second-most
important attribute of DMDs [49], and as the third-most
important by neurologists and MS nurses [50].
Utility questionnaires have been developed for assessing
health outcomes in the context of economic analyses. A
widely applied generic utility instrument is the EuroQol
5-Dimensions questionnaire (EQ-5D), which provides a
descriptive profile for health status based on five questions
regarding mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression, a single index value and a
visual analog scale (VAS) score [51].
Until recently, pivotal trials in MS have tended to lack
measures of HRQoL, and its assessment remains
underutilized in clinical practice. Regulatory authorities
encourage HRQoL assessment in patients with chronic
Table 1 Overview of MS-specific HRQoL questionnaires most commonly used in DMD studies
Instrument No. of
items









54 Generic (SF-36), energy (1), pain (1), sexual
function/satisfaction (5), cognitive function




*15 min No total score; generates two separate
composite scores for physical and mental




Generic (SF-36), fatigue (21), pain (6),
sexual function (4), bladder function (4),
bowel function (4), visual function (5),








No total score; each of the individual
component scales generates a separate
score
FAMS [17] 59 Symptoms (7), mobility (7), family/social
wellbeing (7), general contentment (7),
thinking/fatigue (9), emotional wellbeing
(7), additional concerns (15)
Past 7
days
20–30 min Provides a total score (0–176) based on 44
items, with higher scores indicating better
QoL; the additional-concerns subscale




38 Fatigue/thinking (4), mobility of lower limbs
(5), mobility of upper limbs (5), social
function (6), mood (8), sensory symptoms
(2), bladder/bowel control/sexuality (3),
main symptoms (1), recent health changes




20 min Provides a total score (0.00–5.00) based on
five main subdomains; higher scores
indicate poorer QoL; clinically relevant
change defined as[0.22 change in total
score from baseline [78]
LMSQoL
[19]
8 Family/social (2), fatigue/energy (2),




*2 min Provides a total score (0–32); higher scores
indicate better QoL; clinically relevant








5–10 min A combined score can be generated, or both
components can be reported separately
(0–100); higher scores indicate greater
impact of MS; clinically relevant change
defined as C7.5 change from baseline for
physical impact score [60]
MusiQoL
[21]
31 Physical (8), symptoms (4), psychological




*5 min Provides a total score (0–100); higher scores
indicate better QoL
DMD disease-modifying drug, FAMS Functional Assessment of Multiple Sclerosis, HAQUAMS Hamburg Quality of Life Questionnaire in
Multiple Sclerosis, HRQoL health-related quality of life, LMSQoL Leeds Multiple Sclerosis Quality of Life, MS multiple sclerosis, MSIS-29
Multiple Sclerosis Impact Scale-29, MSQLI Multiple Sclerosis Quality of Life Inventory, MSQoL-54 Multiple Sclerosis Quality of Life-54,
MusiQoL Multiple Sclerosis International Quality of Life, QoL quality of life, SF-36 Medical Outcomes Study Short-Form (36-item) Health
Survey
a Short form
b All domain items refer to the past week; however, the questionnaire contains two items asking about changes in health status within the past
month and the past year
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illnesses as this can provide additional information from
the patient’s own perspective regarding the impact of the
disease and of therapeutic interventions on symptoms and
functions that would not be evaluated using observer-based
instruments. In MS, the relevance of HRQoL as an overall
subjective measure is underpinned by studies showing that
improvement in HRQoL during treatment with DMDs was
accompanied by improvements in fatigue, depression or
cognition [52–55].
PROs are increasingly being used in randomized con-
trolled trials (RCTs) to establish the (added) value of a drug
from the patient perspective. However, as RCTs in MS are
designed and powered to detect changes in MRI abnor-
malities (phase II) or in ARR and time to sustained dis-
ability progression (phase III), changes in secondary and
tertiary outcomes, such as PROs, may fail to be statistically
significant. Moreover, due to their experimental settings
and limited time frames, RCTs cannot adequately evaluate
the effects of DMD treatment in real life. Observational
and controlled effectiveness studies take into account
variables relating to real-life conditions, and may therefore
better inform about the clinical impact of a treatment.
This paper reviews published data regarding the impact
of currently available DMDs on HRQoL in patients with
MS, with a focus on implications for clinical practice. To
identify studies, a literature search was undertaken in
PubMed on 24 April 2017 using the following terms:
‘disease modifying’ or drug name in title (i.e. interferon,
peginterferon, glatiramer, natalizumab, fingolimod, dime-
thyl fumarate or BG-12, teriflunomide, alemtuzumab,
daclizumab, ocrelizumab, mitoxantrone) AND multiple
sclerosis AND (quality of life OR health related quality of
life OR health impact). Controlled trials or observational
studies that provided data on the efficacy of DMDs or the
effectiveness of DMD treatment regarding HRQoL were
retrieved for review. Further articles were sought via
manual searching of retrieved publications. Only articles
written in English were considered, and there was no time
restriction.
The literature search identified 37 publications that
provided sufficient data for inclusion in this review. Data
on study characteristics, HRQoL instrument(s) used,
baseline values, absolute changes or differences, and sta-
tistical significance and clinical relevance of changes or
differences were reviewed. Data are presented for each
DMD in order of market authorization (except for the IFNb
products, which are grouped together) and are summarized
in Tables 2 and 3. RCTs are presented first, followed by
observational studies. The reviewed studies differ consid-
erably in design, duration of follow-up and HRQoL
instrument, making it difficult to compare the DMDs. In
view of the interpretative difficulties, the various studies
are described in detail, so that the readers can make their
own judgment. For practical reasons, only dosages and
regimens that have obtained market authorization are
included. Finally, although statistically significant changes
in HRQoL have been reported in numerous DMD studies in
MS, the actual mean change from baseline may be
numerically small. The minimum clinically important dif-
ference (MCID) is the minimum difference that the patient
is able to recognize and appreciate [56], and this measure
reflects a threshold for an increase to be qualified as
improvement. Reported data on HRQoL improvement
during treatments are summarized at the end of each DMD
section.
2 Impact of DMDs on Health-Related Quality
of Life
2.1 Interferon b
Five RCTs (three in RRMS and two in SPMS) and nine
observational studies in RRMS were identified that pro-
vided data on HRQoL during treatment with IFNb.
Three RCTs assessed the impact of IFNb on HRQoL in
patients with RRMS [57–59]. In a 2-year, randomized,
double-blind, placebo-controlled Multiple Sclerosis Col-
laborative Research Group study in patients with RRMS,
treatment with intramuscular IFNb-1a resulted in a
decrease in mean (standard deviation [SD]) physical SIP
score (-3.78 [8.1]) in patients with baseline SIP scores
C10, which was greater than that in placebo-treated
patients (p\ 0.045) [57]. The changes in overall (-4.45
[8.1]) and psychosocial (-5.86 [12.6]) SIP scores showed a
trend towards significance. In a randomized study of 90
patients with newly diagnosed RRMS treated with intra-
muscular IFNb-1a, subcutaneous IFNb-1a or IFNb-1b for
12 months, mean (SD) MCS of the MSQoL-54 increased
from 58.89 (24.31) to 72.93 (28.12) in the IFNb-1b group
(p = 0.024) [58]. In the phase III ADVANCE study, 1512
patients with RRMS were treated with subcutaneous
pegylated IFNb-1a or placebo every 2 or 4 weeks for
48 weeks [59]. Between-group differences in mean change
from baseline in physical and psychological MSIS-29
scores were not statistically significant [60].
Two RCTs assessed the impact of IFNb on HRQoL in
patients with SPMS [61, 62]. In one study, 718 patients
were treated with IFNb-1b or placebo for up to 36 months
[61]. The SIP total score remained unchanged; however,
IFNb-1b was associated with a greater decrease than pla-
cebo in the score for the physical component at 6, 12 and
36 months, and the psychosocial component at 18 months
(all p B 0.05) [61]. In the second study, 436 patients were
randomized to treatment with intramuscular IFNb-1a or
placebo for 24 months [62]; changes in 8 of 11 MSLQI



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































592 P. J. Jongen
subscales favored intramuscular IFNb-1a at 24 months (all
p\ 0.05), including the SF-36 MCS (0.39 [9.1] in the
intramuscular INFb-1a group compared with -1.6 [9.7] in
the placebo group).
In an early observational study in 51 RRMS patients
treated with intramuscular IFNb-1a or subcutaneous IFNb-
1b [63], an increase in mean (SD) role-physical functioning
subscore of the SF-36 was observed after 6 months, from
33.3 (42.0) to 48.5 (41.9) [p = 0.032], with no changes in
PCS, MCS or other subscores. In another observational
study in 182 patients with RRMS and 28 patients with
SPMS who were treated with intramuscular IFNb-1a
(n = 18), subcutaneous IFNb-1a (n = 50), IFNb-1b
(n = 99) or GA (n = 8) for up to 3 years [64], an increase
in mean LMSQoL score was observed after 1 month
(p = 0.0001), which was sustained over the follow-up
period, with no differences observed between DMDs. In
contrast, an observational study of 27 RRMS patients
treated with intramuscular IFNb-1a reported no change in
mean FAMS score at 6 or 12 months [65], and another
study of 121 patients with RRMS reported no negative
impact of intramuscular IFNb-1a treatment on SF-36
scores [66].
Recent observational studies have generally shown
treatment with IFNb to be associated with positive changes
in HRQoL in RRMS, most commonly assessed using the
MSQoL-54. In a study of neurological practices in The
Netherlands, Belgium, UK and Luxembourg, mean (SD)
MSQoL-54 PCS increased from 56.6 (16.6) to 61.0 (17.7)
[p\ 0.05] and MCS from 57.2 (16.6) to 61.1 (16.1)
[p = 0.07] over 2 years of treatment with intramuscular
IFNb-1a in 284 patients with RRMS [67]. In the COGI-
MUS study conducted in Italy [68], mean MSQoL-54 PCS
and MCS remained stable in 331 patients with mild RRMS
treated with subcutaneous IFNb-1a for 3 years (mean [SD]
baseline PCS 69.4 [15.8], MCS 66.1 [19.1]). Increases in
MSQoL-54 PCS and MCS were reported after 2 years of
treatment with intramuscular or subcutaneous IFNb-1a in
another observational study in 394 patients with RRMS in
Italy [69]. Mean change in PCS at 2 years was ?3.1 and
?3.0 in the intramuscular and subcutaneous groups,
respectively (mean [SD] baseline scores 67.1 [14.7] and
64.4 [13.9]; both p\ 0.05). Respective mean changes in
MCS were ?4.7 and ?5.5 (mean [SD] baseline scores 67.1
[20.6] and 62.5 [21.6]; both p\ 0.001). No changes were
observed in untreated patients. EDSS progression was
associated with HRQoL deterioration.
The COMPARE study was primarily designed to com-
pare the utility and properties of the MusiQol and MSQoL-
54 in patients with RRMS [70]. In a prespecified secondary
analysis of data from 196 patients [48], an increase was
observed in mean MSQoL-54 PCS and MCS after
24 months of treatment with subcutaneous IFNb-1a
(approximately 4 points for PCS [p = 0.027] and approx-
imately 6 points for MCS [p = 0.0003]; mean [SD] base-
line scores 60.9 [19.7] and 65.6 [20.5], respectively).
A small (Cohen’s d effect size -0.16) mean (SD)
decrease of -1.73 (9.15) in MusiQoL score after 1 year’s
treatment with subcutaneous IFNb-1a was reported in a
recent observational study of 400 patients with RRMS in
Iran [71]. A small (Cohen’s d -0.28) decrease in SF-36
PCS (-5.97 [13.72]) and a moderate (Cohen’s d -0.52)
decrease in MCS (-9.53 [15.37]) were also noted (mean
[SD] baseline scores 78.20 [21.65] and 84.98 [18.06]).
In summary, efficacy of IFNb regarding HRQoL was
demonstrated in one placebo-controlled RCT in RRMS in a
subgroup of patients with low baseline HRQoL [57], and in
two placebo-controlled RCTs in patients with SPMS
[61, 62]. Five of ten effectiveness studies in RRMS
observed an increase in HRQoL during IFNb treatment
[48, 58, 64, 67, 69]; improvements were not reported.
2.2 Glatiramer Acetate
One open-label RCT and three observational studies
reported on HRQoL in patients treated with GA
[55, 72–75]. GLACIER was an open-label, randomized,
prospective study to assess the safety and tolerability of
GA 40 mg three times weekly vs. GA 20 mg daily in
patients with clinically stable RRMS who had been treated
continuously with GA 20 mg daily for at least 6 months
[72]. No changes in physical or psychological well-being
were observed, as assessed using the MSIS-29.
In the prospective 12-month observational FOCUS
study, changes in HRQoL were assessed during treatment
with GA 20 mg daily in 197 patients with RRMS [73, 74].
At 12 months, the mean LMSQoL score was increased in
the treatment-naive group (n = 106) (mean [SD] change
from baseline ?2.10 [4.56]; p\ 0.001) [73]. In addition,
43% of treatment-naive patients showed improved HRQoL
at 12 months (defined as C3-point increase in LMSQoL
score). The increase in HRQoL was associated with a
reduction in fatigue. An extension of this study found that
the changes in HRQoL and fatigue were sustained after
2 years of GA treatment [74]; at this time, the mean
LMSQoL change from baseline was 0.76 SD in treatment-
naive patients (n = 29) and 0.53 SD in pretreated patients
(n = 22).
COPTIMIZE was a 2-year prospective study in patients
with RRMS who switched to GA 20 mg daily from other
DMDs [75], with 218 patients having HRQoL data at
baseline and the final examination. At 24 months, the mean
FAMS score was increased by ?5.95 points (p = 0.0027),
irrespective of previous treatment or reason for switching.
Greater increase was observed in patients who switched to
GA because of adverse effects (?10.81 points; p = 0.0120)
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compared with those who switched due to lack of effec-
tiveness (?6.62 points; not significant), which would
appear to suggest that the resolution of adverse effects
contributed to better HRQoL. Positive changes in fatigue,
depression and cognition were also reported.
QualiCOP was a 2-year, observational, open-label study
in 754 patients with RRMS at 170 sites in Germany [55]
prospectively evaluating, in a real-world setting, the long-
term effectiveness and tolerability of treatment with GA
20 mg daily. HRQoL assessed by FAMS remained
stable over the 2 years of follow-up in the overall popu-
lation and in both pretreated (n = 273) and treatment-naive
patients (n = 481). However, an increase in cognitive
function and decrease in depressive symptoms were
reported during the follow-up period (both p\ 0.001).
In summary, two observational studies in RRMS found
an increase in HRQoL during GA treatment [73–75], and,
in one of these, improvement was observed in patients with
no previous DMD treatment.
2.3 Natalizumab
Three studies on natalizumab treatment and HRQoL were
identified, one RCT and two observational studies
[45, 52, 76]. AFFIRM was a 2-year phase III trial in which
942 relapsing MS patients were randomized to natalizumab
or placebo treatment in a 2:1 ratio [45]. At 104 weeks,
mean SF-36 PCS and MCS were higher in natalizumab-
treated patients (both p\ 0.05) than in those receiving
placebo (mean change ?0.67 vs. -1.34 for PCS, and
?2.00 vs. -0.53 for MCS, respectively; mean baseline
PCS was 43.7 in the natalizumab group and 44.3 in the
placebo group, and mean baseline MCS was 45.7 and 46.8,
respectively). A greater proportion of natalizumab-treated
patients than those on the control regimen experienced a
clinically relevant increase (improvement) in SF-36 PCS
(defined as C0.5 SD change from baseline to week 104;
24.9 vs. 16.8%, respectively; odds ratio [OR] 1.54). An
improvement in SF-36 MCS was observed in 28.5 vs.
21.6% patients, respectively (OR 1.33).
HRQoL data for natalizumab have also been obtained in
clinical practice settings. In an observational study,
increases in SF-12 and MSIS-29 scores were observed after
3 months and sustained over 12 months in 333 patients
with RRMS treated with natalizumab [76]. Mean change in
SF-12 PCS from baseline (34.2) was ?2.4 at 12 months
(p\ 0.0001); respective mean change in SF-12 MCS
(43.2) was ?3.6 (p\ 0.0001). A mean change of -7.1 in
MSIS-29 physical impact score from baseline (47.5) was
observed at 12 months (p\ 0.0001), along with a mean
change of -7.9 in MSIS-29 psychological impact score
(42.0) [p\ 0.0001]. Increases in cognitive functioning and
decrease in fatigue were also reported. Moreover, in this
study, improvement was defined as an increase of C5
points on the SF-12 (range 0–100) and a decrease in at least
one category (i.e. C19 points) on the MSIS-29. Improved
SF-12 PCS and MCS after 12 months were seen in 36 and
39% of patients, respectively, and improved or
stable MSIS-29 physical and psychological impact scores
in 43 and 42%, respectively.
In the recent open-label TYNERGY study in 195 MS
patients, increases in mean SF-12 PCS and MCS from
baseline were reported after 12 months of natalizumab
treatment [52]. Mean change was ?3.89 for SF-12 PCS and
?4.17 for SF-12 MCS (p\ 0.0001); mean baseline scores
were 40.5 and 44.8.
In summary, one placebo-controlled RCT demonstrated
that natalizumab is efficacious in improving physical and
mental HRQoL in RRMS [45]. In one of two observational
studies, approximately 40% of patients showed improved
physical and mental HRQoL after 12 months of natal-
izumab treatment [76].
2.4 Fingolimod
Three RCTs and one observational study reported on
HRQoL during treatment with fingolimod [53, 54, 77, 80,
81].
In a phase II study, 281 RRMS patients were treated for
6 months with placebo or doses of fingolimod that have not
been further studied in a phase III trial (5 mg daily) or have
not been filed for market authorization (1.25 mg daily)
[77]. In this study, clinically relevant HRQoL change
(improvement, deterioration) was defined as a change in
HAQUAMS total score of [0.22 from baseline [78, 79].
Fewer fingolimod-treated patients (17.2% [1.25 mg] and
19.1% [5.0 mg]) had a worsened HRQoL at 6 months than
placebo-treated patients (33.0%; both p\ 0.05); however,
the proportions of improved patients did not differ between
groups (18.3% [1.25 mg], 23.6% [5.0 mg] and 13.6%
[placebo]).
FREEDOMS II was a 2-year, double-blind, placebo-
controlled, phase III study in which 1083 patients with
RRMS were randomized to fingolimod 1.25 mg, fin-
golimod 0.5 mg or placebo [80]. HRQoL was a secondary
outcome and was assessed using the PRIMUS and EQ-5D
questionnaires. No differences were found between the
three treatment groups for these outcomes.
In the open-label randomized Evaluate Patient Out-
Comes study [53, 54], 1053 patients with relapsing forms
of MS treated with intramuscular IFNb-1a, subcutaneous
IFNb-1a, IFNb-1b or GA (20 mg daily) were randomized
to switch to oral fingolimod 0.5 mg (n = 790) or to remain
on IFNb or GA treatment (n = 263). Least-squares mean
changes in SF-36 PCS from baseline to 6 months were
greater in patients who switched than in those who
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remained on subcutaneous IFNb-1a (2.28 vs. 0.07;
p = 0.024) or IFNb-1b (2.51 vs. -0.63; p = 0.022),
whereas no differences were observed between switching
to fingolimod and remaining on GA or intramuscular IFNb-
1a. An increase in SF-36 MCS was seen after switching
compared with remaining on IFNb-1b (2.96 vs. -0.50;
p = 0.03).
In an observational study at an academic medical center
in the US, health status assessed using the EQ-5D remained
stable in a group of 316 patients (81% RRMS) for
12 months after fingolimod initiation [81]. Most patients
(75%) switched directly to fingolimod from another DMD.
In summary, in an open-label RCT, the mean change in
physical HRQoL in patients switching to fingolimod
0.5 mg was higher than in those remaining on subcuta-
neous IFNb-1a or subcutaneous IFNb-1b, and the mean
change in psychological HRQoL was higher than in those
continuing subcutaneous IFNb-1a [53, 54]. Health status
(EQ-5D) has been reported to remain stable after starting
fingolimod treatment [81].
2.5 Dimethyl Fumarate
Four studies on DMF and HRQoL were identified: two
RCTs, an integrated analysis of these trial results, and a
survey study [82–85]. The effect of DMF 240 mg twice
daily on HRQoL (SF-36) in patients with RRMS was
assessed as a tertiary endpoint in two large, 2-year, double-
blind, placebo-controlled, phase III studies (DEFINE and
CONFIRM) [82, 83]. In DEFINE, the 2-year mean change
in PCS in the DMF group was ?0.45 compared with -1.36
in the placebo group (mean [SD] baseline scores 42.9
[10.02] and 43.3 [10.20], respectively; p\ 0.001) [82].
Mean change in MCS was ?0.20 and -1.06 in the DMF
and placebo groups, respectively (mean [SD] baseline
scores 45.3 [10.93] and 45.7 [11.15], respectively;
p\ 0.002). In addition, improved (C5-point increase) PCS
occurred in 24% of DMF-treated vs. 16.2% of placebo-
treated patients (OR 1.8); improved MCS (C5-point
increase) was observed in 30.0 and 20.6%, respectively
(OR 1.93) [82]. In the CONFIRM study [83], the mean
change from baseline in SF-36 PCS at 2 years in the DMF
group was higher than in the placebo group or the group
receiving GA 20 mg once daily (both p\ 0.05). The
proportion of patients with improved (C5-point increase)
PCS did not differ between fingolimod and placebo, or
between GA and placebo.
An integrated analysis of these studies [84] included 769
patients treated with DMF 240 mg twice daily and 771
placebo-treated patients (mean baseline SF-36 PCS and
MCS were approximately 43.0 and approximately 45.0,
respectively). Overall, 21% of DMF-treated patients had an
improved (C5-point increase) PCS vs. 17.6% of patients
receiving placebo (p = 0.0008); an improved MCS was
reported in 26.6 and 23.1% of patients, respectively
(p = 0.0221).
The effectiveness of DMF treatment regarding HRQoL
is suggested by an exploratory analysis of data from a real-
world survey among patients with RRMS and their neu-
rologists. Current treatment duration was at least
12 months. In the DMF group (n = 31), the estimated
average treatment effect for the HAQUAMS total score
was -0.45 (95% CI -0.61 to -0.29) vs. 1.95 (95% CI
1.86–2.04) in patients receiving INFb or GA (n = 229;
p\ 0.001), and 0.075 (95% CI 0.014–0.136) vs. 0.823
(95% CI 0.793–0.852) [p = 0.016] for the EQ-5D index
[85].
In summary, in one RCT in patients with RRMS, DMF
was efficacious in improving physical and mental HRQoL
compared with placebo [82]. An integrated analysis with
data from another RCT confirmed these results [84]. Sur-
vey data suggest the effectiveness of DMF treatment in
increasing HRQoL compared with INFb-1a and GA [85].
2.6 Teriflunomide
Only limited data are available regarding the effect of
teriflunomide on HRQoL. In a phase II long-term extension
study in 147 RRMS patients treated with 7 or 14 mg daily
[86], patients had a mean reduction of 2.0 on the MSQoL-
54 MCS at 7.2 years (effect size 0.11) and a mean reduc-
tion of 6.1 (effect size 0.35) for the PCS. Overall, patients
had minimal disability progression (EDSS) over the study
period.
2.7 Alemtuzumab
Two RCTs provided HRQoL data for alemtuzumab [87].
The two phase III CARE-MS trials with subcutaneous
IFNb-1a 44 lg three times weekly as the comparator [87]
included 563 treatment-naive RRMS patients (CARE-MS
I) and 628 patients with inadequate response to prior DMD
therapy (CARE-MS II). Mean change in FAMS score after
24 months favored alemtuzumab by 4.25 points in CARE-
MS I (p\ 0.05) and by 5.34 points in CARE-MS II
(p\ 0.01); mean (SD) baseline scores in the alemtuzumab
and IFNb-1a groups were 133.4 (27.65) and 134.2 (27.61),
respectively, in CARE-MS I, and 118.8 (31.64) and 118.8
(32.72), respectively, in CARE-MS II. For SF-36 PCS,
between-treatment differences at month 24 favored alem-
tuzumab in CARE-MS II (p\ 0.01). The odds of
improvement (C5-point increase)/remaining stable vs.
worsening on the PCS were greater with alemtuzumab in
CARE-MS II (inadequate response to prior DMD therapy)
[OR 1.69, p = 0.0111], but not in CARE-MS I (OR 1.39,
p = 0.14). For SF-36 MCS, scores at month 24 were
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increased from baseline in both treatment groups in CARE-
MS I (both p B 0.0009) and CARE-MS II (p\ 0.0001 for
alemtuzumab and p = 0.0478 for IFNb-1a). In both trials,
a similar proportion of patients in the two treatment groups
had improved SF-36 MCS at 24 months (CARE-MS I:
32.6% with alemtuzumab vs. 35.2% with IFNb-1a; CARE-
MS II: 35.7% with alemtuzumab vs. 31.6% with IFNb-1a).
Finally, the alemtuzumab-treated groups in both studies
had increased mean EQ-5D index values and EQ-VAS
scores at month 24 (p B 0.05), as did the IFNb-1a-treated
group in the CARE-MS I study (p B 0.05). No difference
in EQ-5D index or VAS scores at month 24 was seen
between treatment groups in CARE-MS I. In contrast, in
CARE-MS II, the mean EQ-VAS score at month 24 was
higher in the alemtuzumab group (p\ 0.05).
In summary, in the RCT in RRMS patients with inad-
equate response to prior therapy (CARE-MS II) [87],
alemtuzumab was more efficacious in improving/stabiliz-
ing physical HRQoL than subcutaneous IFNb-1a. In an
RCT in treatment-naive RRMS patients, alemtuzumab was
efficacious in increasing HRQoL compared with subcuta-
neous IFNb-1a.
2.8 Daclizumab
Two RCTs were identified that provided HRQoL data for
daclizumab [88–90]. Assessment of HRQoL was a tertiary
outcome in the placebo-controlled, double-blind SELECT
study of the efficacy of subcutaneous daclizumab high-
yield process 150 mg every 4 weeks and 300 mg every
4 weeks in 621 patients with RRMS [88, 89]. In the
150 mg group (the dose that has been authorized), the
mean change in SF-12 PCS and MCS after 52 weeks was
?1.2 and ?0.7, respectively (mean [SD] baseline scores
42.9 [9.9] and 46.1 [11.5], respectively) vs. -0.4 and -1.4,
respectively, in the placebo group (mean [SD] baseline
scores 42.5 [10.0] and 46.4 [10.2], respectively); these
differences were statistically significant (both p = 0.012).
Mean changes in MSIS-29 physical and psychological
impact scores were -1.0 and -1.8, respectively, for
daclizumab (mean [SD] baseline scores 24.7 [20.2] and
28.6 [21.5], respectively), and ?3.0 and ?0.6, respectively,
for placebo (mean [SD] baseline scores 26.3 [22.0] and
29.5 [22.5], respectively). The differences between the
groups were statistically significant (physical impact score,
p\ 0.001) or tended towards significance (psychological
impact score, p = 0.068). Further analysis of the trial data
suggested that an increase of C7.5 on the MSIS-29 phys-
ical scale could be considered indicative of clinically rel-
evant increase (deterioration) [60]. Using this MCID, the
proportion of patients with MSIS-29 physical deterioration
at 52 weeks was lower in the daclizumab group than in the
placebo group (20 vs. 28%; p\ 0.01).
DECIDE was a double-blind, phase III trial comparing
daclizumab (n = 919) with intramuscular IFNb-1a 30 lg
once weekly (n = 922) [90]. At week 96, the odds of
patients experiencing a clinically meaningful worsening in
MSIS-29 physical score was lower for the daclizumab
group (OR 0.76, 95% CI 0.60–0.95; p = 0.0176); mean
(SD) baseline score 21.5 (19.8) for the daclizumab group
and 21.9 (19.2) for the intramuscular IFNb-1a group.
Similarly, at week 96, greater changes occurred in the EQ-
5D index value in the daclizumab-treated group than in the
intramuscular IFNb-1a group (p = 0.005; baseline 0.74
[0.22] and 0.75 [0.22], respectively), as well as in the
EQ-5D VAS score (2.69 vs. 0.33; p\ 0.001) (baseline
74.1 [19.7] and 73.7 [18.9], respectively).
In summary, in a placebo-controlled RCT in RRMS,
daclizumab was efficacious in preventing worsening of
physical HRQoL [88, 89]. In another RCT, daclizumab was
efficacious in preventing worsening of HRQoL in com-
parison with intramuscular IFNb-1a [90].
2.9 Ocrelizumab
Three RCTs providing data on ocrelizumab and HRQoL
were identified [91, 92]. In OPERA I and OPERA II (two
identical phase III trials), 821 and 835 patients with RRMS
were randomized to intravenous ocrelizumab 600 mg every
24 weeks, or subcutaneous IFNb-1a 44 lg three times
weekly for 96 weeks [91]. In OPERA I, the adjusted mean
(95% CI) change in SF-36 PCS (a secondary endpoint) in
the ocrelizumab-treated group was ?0.04 (-0.86 to 0.93)
and did not differ from that in the subcutaneous IFNb-1a
group (-0.66 [-1.59 to 0.28]; p = 0.22). In contrast, in
OPERA II, the adjusted mean (95% CI) change was higher
in the ocrelizumab group (0.33 [-0.55 to 1.20]) than in the
subcutaneous IFNb-1a group (-0.83 [-1.76 to 0.09];
p = 0.04). In the phase III ORATORIO trial, 732 patients
with PPMS were randomized (2:1) to receive intravenous
ocrelizumab 600 mg or placebo every 24 weeks for at least
120 weeks [92]. The adjusted mean (95% CI) change in the
secondary endpoint SF-36 PCS did not differ between the
groups, being -0.73 (-1.66 to 0.19) in the ocrelizumab-
treated group, and -1.11 (-2.39 to 0.18) in the placebo
group (p = 0.60). SF-36 MCS values were not reported in
these trials.
In summary, in one of two RCTs in RRMS (OPERA II),
ocrelizumab was efficacious relative to subcutaneous
IFNb-1a in increasing physical HRQoL [91].
2.10 Mitoxantrone
No studies were identified reporting HRQoL data for
mitoxantrone.
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3 Discussion
In general, the above data show that DMDs may have a
positive and beneficial impact on HRQoL in patients with
RRMS. For the first-generation DMDs (IFNb-1b, intra-
muscular IFNb-1a, subcutaneous IFNb-1a, and GA 20 mg
daily), there is little RCT evidence that these drugs may
cause an increase in HRQoL (Table 3); however, most
post-authorization studies suggest that real-life use is
indeed associated with stabilizing or increasing HRQoL.
This discrepancy is most likely due to the fact that when
the respective phase III trials were conducted, the scientific
community was less aware of the relevance of HRQoL as a
desirable additional study outcome. The impact on HRQoL
has been more systematically investigated in pivotal RCTs
for most of the DMDs authorized since 2004 (natalizumab,
fingolimod, DMF, alemtuzumab, daclizumab and ocre-
lizumab). However, as might be expected, few studies have
yet investigated the effectiveness of treatment with the
more recently approved DMDs in daily practice regarding
HRQoL.
While HRQoL endpoints are increasingly being used in
clinical trials, results are not always reported in terms of
clinical relevance [56, 93, 94]. A change in score equiva-
lent to 0.5 SD has been found to have almost universal
relevance as an MCID for HRQoL [94, 95]. This has been
related to psychophysiological evidence that the human
limit of cognitive discrimination is approximately one part
in seven, which, in many empirical circumstances, is
approximately 0.5 SD [94, 95]. Using the 0.5 SD threshold
for the SF-36, a change of C5 points in PCS and MCS has
been proposed to be clinically meaningful [95]. Applying
this MCID in phase III studies, approximately 25–35% of
patients had improved SF-36 PCS and MCS after 2 years
of treatment with natalizumab [45], fingolimod [77], DMF
[84] and alemtuzumab [87]. Using anchor- and distribu-
tion-based methods, the MCID of the MSIS-29 physical
impact subscale was found to be C7.5 [60], and, with the
use of an anchor-based method, an MCID of C0.22 was
established for the HAQUAMS [78].
To evaluate the clinical relevance of statistically sig-
nificant changes, we compared the data on improvements
in HRQoL for first-line vs. second-line DMDs. Thus, while
five of ten effectiveness studies on HRQoL during IFNb
treatment noted a statistically significant increase
[48, 58, 64, 67, 69], none has documented changes that
qualified as clinically meaningful. Similarly, while three
observational studies found an increase in HRQoL during
treatment with GA 20 mg daily [55, 73–75], actual
improvements were only observed in one subgroup in one
study, namely patients with no previous DMD treatment.
As to the impact of second-line DMDs, improvement in
HRQoL has been documented in the phase III placebo-
controlled trial, and also in the two observational studies
that included HRQoL as a treatment outcome for natal-
izumab [45, 52, 76]; in one of two RCTs, alemtuzumab was
more efficacious in improving or stabilizing physical
HRQoL than subcutaneous IFNb-1a in patients with
inadequate response to prior therapy [87]; daclizumab was
efficacious in preventing worsening of physical HRQoL in
a placebo-controlled RCT, and was more efficacious than
intramuscular IFNb-1a in preventing worsening HRQoL in
another RCT [88–90]. The reviewed data therefore suggest
that in RRMS, second-line DMDs generally have a greater
impact on HRQoL than the first-line drugs.
There is not necessarily a direct relationship between
treatment effectiveness in terms of ARR reduction or
delayed disability progression and HRQoL improvement. It
may well be that therapeutic changes are partially out-
weighed by adverse effects. For example, in the SENTI-
NEL study, combination therapy with natalizumab and
intramuscular IFNb-1a was associated with a lower ARR
than intramuscular IFNb-1a alone, and with fewer new or
enlarging MRI lesions [45]. However, while a greater
proportion of combination-treated patients experienced an
improvement in SF-36 PCS (defined as C0.5 SD increase),
namely 23.3 vs. 17.4% (OR 1.47), respective proportions
of patients with an improved SF-36 MCS were 17.1 vs.
21.0% (OR 0.99). Notably, some potentially bothersome
adverse events occurred more frequently in the combina-
tion group, namely anxiety, pharyngitis, sinus congestion
and peripheral oedema [45]. The fact that improvements in
physician-reported and MRI measures in patients who
received combination therapy were not mirrored by an
increase in mental HRQoL suggests that, from the patients’
perspective, the benefit of less frequent relapses might have
been outweighed by adverse events. This interpretation is
in line with a report that patients who switched to another
DMD because of adverse effects showed a greater increase
in HRQoL than those who converted due to lack of
effectiveness [75].
Overall, these research data seem to underline the con-
tribution of HRQoL assessment to a more integrated
evaluation of DMD treatment in clinical practice. As
HRQoL is a comprehensive quantification of the patient’s
experiences regarding disease and treatment, HRQoL data
can contribute to the process of shared decision making,
and thus help clinical management decisions, such as
whether to initiate, continue or switch DMD treatment. The
unique contribution of HRQoL assessment to the evalua-
tion of individual patients is illustrated by the fact that a
permanent numbness at a fingertip will hardly have a
functional effect in a construction worker, but may severely
affect the occupational activities of a professional violinist.
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Recently, it has been reported that the levels of HRQoL
and self-efficacy may predict the risk of early treatment
discontinuation in patients starting high-frequency GA
treatment [96]. When interpreting HRQoL changes over
longer periods, response shift may be a concern as sub-
jective self-reported outcomes may be influenced by
adaptation to the illness [97], even in patients who are not
actively experiencing symptoms on a consistent basis [98].
Given the nature of the underlying concept, the inter-
pretation of HRQoL may pose difficulties in the context of
contrary observer-reported data. Discrepancies between
changes in EDSS score and HRQoL may be due to DMD
adverse effects or to the fact that changes experienced by
the patient are not adequately reflected by the EDSS, as
outlined above. For example, the occurrence of depressive
symptoms during IFNb treatment will negatively affect
HRQoL, but less so the EDSS score. Similarly, improve-
ment in fatigue during GA treatment is likely to have a
greater positive impact on HRQoL than on the EDSS score.
The understanding of conflicting or unexpected HRQoL
outcomes may be facilitated by the assessment of depres-
sion, anxiety, fatigue and cognition, e.g. via the Hospital
Anxiety and Depression Scale (HADS), Modified Fatigue
Impact Scale (MFIS) and the Symbol Digit Modalities
Test, respectively. These symptoms are not only major
factors contributing to HRQoL but also are underestimated
by the EDSS.
As stated, a large number of HRQoL instruments have
been developed for use in patients with MS. In fact, this
abundance of instruments may constitute a barrier to their
use in clinical practice, with no particular instrument
having gained widespread popularity or consensus recom-
mendation. Conceptually, it seems reasonable to assume
that MS-specific questionnaires are more appropriate than
generic instruments as they focus on disease-specific health
problems. The MSQoL-54 and MusiQoL questionnaires
are both available in a number of languages, which may
facilitate their wider use. In a recent study [70], patients
found the shorter MusiQoL easier to use than the MSQoL-
54, suggesting that a shorter questionnaire may be more
appropriate for use in daily practice. A novel instrument
that combines elements of the Center for Epidemiologic
Studies Depression Scale, the Medical Outcomes Study
Modified Social Support Survey, the MFIS, and the
MSQoL-54 is under investigation [99].
In general, lack of time and resources are major con-
straints on the standard use of HRQoL questionnaires in
clinical practice [7]. To some extent, this may be overcome
by making questionnaires available online so that they can
be completed at home or at the clinic before the consul-
tation. Furthermore, with online assessments, errors and
missing data are minimized by automated checks of com-
pleteness and consistency, and scores are calculated
automatically and can be displayed graphically. A shorter
electronic version of the MSQoL-54 with automatic scor-
ing (the MSQoL-29, which preserves key HRQoL dimen-
sions) is currently being validated [100]. A
multidimensional computerized adaptive short-form ver-
sion of the MusiQoL is also under development [101].
Online monitoring by use of PROs appears feasible in
patients with MS. In a study that investigated whether
patients with RRMS would adhere to the monthly online
completion of two short questionnaires to monitor the
effectiveness of DMD treatment, 75% of patients per-
formed all assessments during the 12 months of follow-up
[102]. Sending SMS or email reminders may further
increase compliance. However, embedding PRO monitor-
ing into daily care processes and consistent utilization of
outcomes by healthcare professionals during their consul-
tations seems even more important. Thus, two HRQoL
questionnaires (MSQoL-54, LMSQoL) form part of
MSmonitor, an interactive web-based program for self-
management and integrated multidisciplinary care in
patients with MS [103, 104]. This program, which also
includes, among others, the HADS and MFIS-5, is being
used successfully in The Netherlands.
Based on the above, a set of guidelines may be sug-
gested for the assessment of HRQoL in daily MS care.
Ideally, the questionnaire used should be one for which the
MCID has been established, that is available for online
completion, and that is embedded in a web-based program
including depression, anxiety, fatigue and cognition scales.
Baseline HRQoL should be assessed at the time of diag-
nosis, before starting or switching DMD treatment, and
possibly also to help identify patients at high risk of early
treatment discontinuation. Monitoring of HRQoL via
assessments at regular intervals enables the detection of
improvements and deteriorations, the latter being warning
signs for an increase in disability. HRQoL outcomes need
to be interpreted in relation to symptoms and adverse
treatment effects, and discussed with patients during con-
sultations. They contribute to an integrated evaluation of
disease course and/or treatment effects, and may be used in
the process of shared decision making.
These proposed measures may be thought of as complex
interventions that have to be investigated for their feasi-
bility, effectiveness and cost effectiveness, e.g. via mixed-
methods methodology and RCTs. Other topics that may be
subjects for future research are the establishment of MCIDs
for all available HRQoL instruments; the further develop-
ment of short, specific or adaptive questionnaires; the
further assessment of the predictive value of HRQoL
worsening regarding disability progression; and the con-
tribution of HRQoL to risk stratification with respect to
early DMD discontinuation. Interestingly, it has been
argued recently that the MCID for a particular PRO
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instrument is not an immutable characteristic, but may vary
by population and context, including the clinical context,
decision at hand, the baseline from which the patient starts,
and whether he or she is improving or deteriorating [94].
For such a personalized application of HRQoL to become
reality, it seems necessary, among others, to obtain national
or regional reference values. Data from patient registries,
such as the North American Research Committee on
Multiple Sclerosis (NARCOMS), Patients Like Me, and the
Swedish MS Registry [105–107], and from longitudinal,
web-based, patient-centred studies [108] may provide such
information about HRQoL over the disease course and the
impact of DMDs. For example, recent data for almost 4000
patients from the NARCOMS registry suggest that pre-
venting, or at least minimizing, HRQoL decline in the early
stages of the disease may be the best way to ensure high
levels of HRQoL over time [107].
4 Conclusion
HRQoL quantifies subjective aspects of the patient’s health
status. Data from RCTs and observational studies in RRMS
indicate that DMD treatment is associated with prevention
of worsening or with improvement of HRQoL. Despite
differences in design, duration of follow-up and HRQoL
instrument, studies suggest that, in general, second-line
DMDs may have a greater impact on HRQoL than first-line
DMDs. In clinical practice, monitoring of HRQoL provides
clinicians with unique information regarding disease
impact and the potential benefits and adverse effects of
DMD treatment that may not be obtained otherwise, and
might also permit early detection of an unfavorable disease
course. HRQoL assessment may help to elucidate and
quantify the patient’s contribution to shared decision
making regarding DMD treatment. Further studies are
needed to better determine the role of HRQoL assessments
in daily MS care.
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